On March 19, 2018 Obsidian Therapeutics, Inc., a biotechnology company dedicated to the development of next-generation cell and gene therapies with pharmacologic operating systems, reported that the company will participate in two upcoming investor conferences (Press release, , 19 19, 2018, View Source [SID1234524897]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Obsidian will participate in two conferences: BioCentury Future Leaders in the Biotech Industry Conf. 3/23, and Jefferies IO Cell Therapy Summit 4/3.

Tweet this
On Friday, March 23, 2018, at 11:30 a.m. ET, Michael Gilman, Ph.D., Chief Executive Officer, will present a company overview at BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel & Conference Center in New York, NY. A breakout session will follow the presentation at 12:00 noon.

On Tuesday, April 3, 2018, Dr. Gilman will also make a presentation on Obsidian at 3:15 p.m. ET at the Jefferies IO Cell Therapy Summit, an event focused on novel therapeutics in the immuno-oncology space, at the Boston Harbor Hotel in Boston.